Welcome to our dedicated page for Rain Enhancement Technologies Holdco news (Ticker: RAIN), a resource for investors and traders seeking the latest updates and insights on Rain Enhancement Technologies Holdco stock.
Rain Enhancement Technologies Holdco, Inc. develops, manufactures, and commercializes ionization precipitation generation technology for rainfall and snowpack enhancement. Its updates center on the Weather Enhancement Technology Array (WETA), U.S. installations, weather-modification permits, independent analyses of agricultural water benefits, and reported precipitation results in mountain and arid environments.
The company also reports research into adjacent atmospheric applications, including fog mitigation and air pollution or smog mitigation. Governance updates and commercialization milestones appear alongside technical disclosures about its chemical-free, solar-powered ionization approach.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Rain Oncology Inc. (NASDAQ: RAIN) announced that it will report its first quarter financial results for the period ending March 31, 2023, along with updates on its business on May 11, 2023. The company is focused on developing precision oncology therapeutics, particularly its lead candidate, milademetan, which inhibits the MDM2-p53 complex to reactivate p53. A conference call and webcast will follow the earnings release, scheduled for 2:00 PM PT (5:00 PM ET) on the same day. Investors can access the call via phone or through the provided webcast link. Rain's strategy involves a tumor-agnostic approach, selecting patients based on tumor genetics.
Rain Oncology Inc. (NasdaqGS: RAIN) announced a poster presentation at the upcoming AACR Annual Meeting 2023, scheduled from April 14-19 in Orlando, Florida. The poster, presented by Dr. Arielle Elkrief from Memorial Sloan Kettering Cancer Center, focuses on MDM2 inhibition and MEK inhibition in preclinical models of lung adenocarcinomas. The presentation, titled “MDM2 inhibition in combination with MEK inhibition in preclinical models of lung adenocarcinomas with MDM2 amplification”, is set for April 19 at 9:00 A.M. ET. The details will be accessible on Rain's website post-presentation.